In a pilot study of ER+ metastatic breast cancer patient-derived CTCs, we observe a lysis–hardy CTC phenotype and the unique capacity to normalize target protein expression by the number of CTCs analysed per assay, just one CTC per scWB microwell here. The gene discussed is ESR1; the disease is breast cancer.